296 related articles for article (PubMed ID: 22811501)
21. Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education Program.
Blonde L; Dempster J; Gallivan JM; Warren-Boulton E
J Am Acad Nurse Pract; 2006 Nov; 18(11):524-33. PubMed ID: 17064330
[TBL] [Abstract][Full Text] [Related]
22. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Morimoto T; Fukui T; Lee TH; Matsui K
Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
[TBL] [Abstract][Full Text] [Related]
23. Worksite health and wellness in the European union.
Guazzi M; Faggiano P; Mureddu GF; Faden G; Niebauer J; Temporelli PL
Prog Cardiovasc Dis; 2014; 56(5):508-14. PubMed ID: 24607015
[TBL] [Abstract][Full Text] [Related]
24. [Prevention of cardiovascular disease in type 2 diabetic patients].
Yokota C
Nihon Rinsho; 2003 Jul; 61(7):1161-6. PubMed ID: 12877078
[TBL] [Abstract][Full Text] [Related]
25. The impact of public smoking ban on the incidence of myocardial infarction hospitalizations.
Khawaja O; Al-Mallah M
Rev Cardiovasc Med; 2010; 11(3):e121-9. PubMed ID: 21045764
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular risk assessment: audit findings from a nurse clinic--a quality improvement initiative.
Waldron S; Horsburgh M
J Prim Health Care; 2009 Sep; 1(3):226-31. PubMed ID: 20690387
[TBL] [Abstract][Full Text] [Related]
27. Current trends in reducing cardiovascular risk factors in the United States: focus on worksite health and wellness.
Cahalin LP; Myers J; Kaminsky L; Briggs P; Forman DE; Patel MJ; Pinkstaff SO; Arena R
Prog Cardiovasc Dis; 2014; 56(5):476-83. PubMed ID: 24607011
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice.
Semb AG; Rollefstad S; van Riel P; Kitas GD; Matteson EL; Gabriel SE
Ann Rheum Dis; 2014 Jul; 73(7):1284-8. PubMed ID: 24608403
[TBL] [Abstract][Full Text] [Related]
29. The New 2019 AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease.
Bittner V
Circulation; 2020 Dec; 142(25):2402-2404. PubMed ID: 30879338
[No Abstract] [Full Text] [Related]
30. Review of an article: aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association (ADA), a scientific statement of the American Heart Association(AHA), and an expert consensus document of the American College of Cardiology Foundation (ACCF). Diabetes Care, 33:6; June 2010; 1395-1402.
Gilpin VL; ; ;
J Vasc Nurs; 2010 Dec; 28(4):154-5. PubMed ID: 21074118
[No Abstract] [Full Text] [Related]
31. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
U.S. Preventive Services Task Force
Am J Nurs; 2002 Mar; 102(3):67, 69-70. PubMed ID: 11976531
[No Abstract] [Full Text] [Related]
32. An ounce of prevention.
Fuster V
Nat Rev Cardiol; 2009 Sep; 6(9):553-4. PubMed ID: 19696772
[No Abstract] [Full Text] [Related]
33. Prevention of cardiovascular events in diabetes.
Malcolm J; Meggison H; Sigal R
Clin Evid; 2003 Dec; (10):690-714. PubMed ID: 15555116
[No Abstract] [Full Text] [Related]
34. Prevention of cardiovascular events in diabetes.
Sigal R; Malcolm J; Arnaout A
Clin Evid; 2006 Jun; (15):623-45. PubMed ID: 16973029
[No Abstract] [Full Text] [Related]
35. [Health policy interventions: the pathway to public health].
Andersen K; Gudnason V
Laeknabladid; 2013 Mar; 99(3):129-34. PubMed ID: 23486685
[TBL] [Abstract][Full Text] [Related]
36. [Primary prevention of cardiovascular disease].
Gohlke H
Dtsch Med Wochenschr; 2005 Jan; 130(1-2):38-43. PubMed ID: 15619173
[No Abstract] [Full Text] [Related]
37. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Moyad MA; Merrick GS
Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
[TBL] [Abstract][Full Text] [Related]
39. Best practice for prevention and treatment of cardiovascular disease through an equity lens: a review.
Beauchamp A; Peeters A; Tonkin A; Turrell G
Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):599-606. PubMed ID: 20562629
[TBL] [Abstract][Full Text] [Related]
40. The young at risk of CVD are the least likely to receive preventive cardiovascular medications in New Zealand.
Hobbs FD
J Prim Health Care; 2011 Jun; 3(2):92. PubMed ID: 21625655
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
